Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 6,000 shares, an increase of 33.3% from the August 15th total of 4,500 shares. Based on an average daily trading volume, of 11,300 shares, the short-interest ratio is currently 0.5 days. Approximately 0.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Aptorum Group

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. acquired a new position in shares of Aptorum Group Limited (NASDAQ:APM) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned 0.27% of Aptorum Group at the end of the most recent reporting period. 3.80% of the stock is currently owned by institutional investors.

Aptorum Group Stock Performance

Shares of NASDAQ:APM traded down $0.12 during midday trading on Monday, hitting $2.76. The stock had a trading volume of 35,743 shares, compared to its average volume of 871,749. Aptorum Group has a 1 year low of $1.35 and a 1 year high of $17.49. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.20. The stock has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $4.89.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.